Abstract

The MARCH E3 ubiquitin (Ub) ligase MARCH1 regulates trafficking of major histocompatibility complex class II (MHC II) and CD86, molecules of critical importance to immunity. Here we show, using a genome-wide CRISPR knockout screen, that ubiquitin-like protein 3 (UBL3) is a necessary component of ubiquitination-mediated trafficking of these molecules in mice and in humans. Ubl3-deficient mice have elevated MHC II and CD86 expression on the surface of professional and atypical antigen presenting cells. UBL3 also regulates MHC II and CD86 in human dendritic cells (DCs) and macrophages. UBL3 impacts ubiquitination of MARCH1 substrates, a mechanism that requires UBL3 plasma membrane anchoring via prenylation. Loss of UBL3 alters adaptive immunity with impaired development of thymic regulatory T cells, loss of conventional type 1 DCs, increased number of trogocytic marginal zone B cells, and defective in vivo MHC II and MHC I antigen presentation. In summary, we identify UBL3 as a conserved, critical factor in MARCH1-mediated ubiquitination with important roles in immune responses.

Regulated trafficking of major histocompatibility complex class II and CD86 is a prerequisite of antigen presenting cell functionality. Authors show here that ubiquitin-like protein 3 is critically involved in the ubiquitination process that controls trafficking, with wide-ranging immunological consequences.

Details

Title
Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86
Author
Liu Haiyin 1   VIAFID ORCID Logo  ; Wilson, Kayla R 1   VIAFID ORCID Logo  ; Firth, Ashley M 1   VIAFID ORCID Logo  ; Macri Christophe 1 ; Schriek, Patrick 1 ; Blum, Annabelle B 1   VIAFID ORCID Logo  ; Villar Javiera 2   VIAFID ORCID Logo  ; Wormald, Samuel 3 ; Shambrook Mitch 4 ; Xu Bangyan 1   VIAFID ORCID Logo  ; Lim, Hui Jing 5   VIAFID ORCID Logo  ; McWilliam, Hamish E, G 6   VIAFID ORCID Logo  ; Hill, Andrew F 4   VIAFID ORCID Logo  ; Edgington-Mitchell, Laura E 7 ; Caminschi Irina 8 ; Lahoud, Mireille H 8   VIAFID ORCID Logo  ; Segura Elodie 2   VIAFID ORCID Logo  ; Herold, Marco J 9   VIAFID ORCID Logo  ; Villadangos, Jose A 6   VIAFID ORCID Logo  ; Mintern, Justine D 1   VIAFID ORCID Logo 

 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 PSL Research University, INSERM, U932, Institut Curie, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889) 
 La Trobe University, Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Bundoora, Australia (GRID:grid.1018.8) (ISNI:0000 0001 2342 0938) 
 The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute, Department of Biochemistry and Pharmacology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); New York University College of Dentistry, Department of Oral and Maxillofacial Surgery, Bluestone Center for Clinical Research, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); Monash University, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 Monash University, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2649216962
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.